{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T15:04:19Z","timestamp":1784991859443,"version":"3.55.0"},"reference-count":185,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"National Science Centre, Poland","doi-asserted-by":"publisher","award":["2019\/03\/X\/NZ7\/00650"],"award-info":[{"award-number":["2019\/03\/X\/NZ7\/00650"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The molecular initiators of Head and Heck Squamous Cell Carcinoma (HNSCC) are complex. Human Papillomavirus (HPV) infection is linked to an increasing number of HNSCC cases, but HPV-positive tumors generally have a good prognosis. External factors that promote the development of HPV-negative HNSCC include tobacco use, excessive alcohol consumption, and proinflammatory poor oral hygiene. On a molecular level, several events, including the well-known overexpression of epidermal growth factor receptors (EGFR) and related downstream signaling pathways, contribute to the development of HNSCC. Conventional chemotherapy is insufficient for many patients. Thus, molecular-based therapy for HNSCC offers patients a better chance at a cure. The first molecular target for therapy of HNSCC was EGFR, inhibited by monoclonal antibody cetuximab, but its use in monotherapy is insufficient and induces resistance. This article describes attempts at combinatorial molecular targeted therapy of HNSCC based on several molecular targets and exemplary drugs\/drug candidates. The new concept of anakoinosis-based therapy, which means treatment that targets the intercellular and intracellular communication of cancer cells, is thought to be the way to improve the clinical outcome for HNSCC patients. The identification of a link between molecular targeted therapy and anakoinosis raises the potential for further progress in HPV-negative HNSCC therapy.<\/jats:p>","DOI":"10.3390\/cancers15174247","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T10:23:40Z","timestamp":1692872620000},"page":"4247","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Advantages of the Combinatorial Molecular Targeted Therapy of Head and Neck Cancer\u2014A Step before Anakoinosis-Based Personalized Treatment"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6607-7436","authenticated-orcid":false,"given":"Robert","family":"Kleszcz","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Biochemistry, Poznan University of Medical Sciences, 4, \u015awi\u0119cickiego Str., 60-781 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrc.2018.11","article-title":"The molecular landscape of head and neck cancer","volume":"18","author":"Leemans","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","article-title":"Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A systematic analysis for the global burden of disease study","volume":"3","author":"Fitzmaurice","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e89829","DOI":"10.1172\/jci.insight.89829","article-title":"The head and neck cancer immune landscape and its immunotherapeutic implications","volume":"1","author":"Mandal","year":"2016","journal-title":"JCI Insight"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.7150\/ijbs.58077","article-title":"Therapeutic strategies of different HPV status in Head and Neck Squamous Cell Carcinoma","volume":"17","author":"Sun","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"113179","DOI":"10.1016\/j.fct.2022.113179","article-title":"Carcinogenic components of tobacco and tobacco smoke: A 2022 update","volume":"165","author":"Li","year":"2022","journal-title":"Food Chem. Toxicol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"681","DOI":"10.4103\/ijmr.IJMR_149_18","article-title":"Carcinogenicity of smokeless tobacco: Evidence from studies in humans & experimental animals","volume":"148","author":"Straif","year":"2018","journal-title":"Indian J. Med. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1146\/annurev.pathol.4.110807.092158","article-title":"Molecular Pathology of Head and Neck Cancer: Implications for Diagnosis, Prognosis, and Treatment","volume":"4","author":"Pai","year":"2009","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1535-6108(02)00102-2","article-title":"The RB and p53 pathways in cancer","volume":"2","author":"Sherr","year":"2002","journal-title":"Cancer Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/PPO.0000000000000115","article-title":"Prevalence of Human Papillomavirus in Oropharyngeal Cancer","volume":"21","author":"Stein","year":"2015","journal-title":"Cancer J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1002\/ijc.28811","article-title":"High-risk HPV types and head and neck cancer","volume":"135","author":"Michaud","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"864","DOI":"10.20892\/j.issn.2095-3941.2020.0370","article-title":"Biological and clinical aspects of HPV-related cancers","volume":"17","author":"Szymonowicz","year":"2020","journal-title":"Cancer Biol. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.gde.2013.11.014","article-title":"Mutational signatures: The patterns of somatic mutations hidden in cancer genomes","volume":"24","author":"Alexandrov","year":"2014","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1021\/acs.chemrestox.3c00021","article-title":"Dissection of Cancer Mutational Signatures with Individual Components of Cigarette Smoking","volume":"36","author":"Mingard","year":"2023","journal-title":"Chem. Res. Toxicol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/ng.2702","article-title":"An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers","volume":"45","author":"Roberts","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.oraloncology.2017.09.002","article-title":"Multi-modality analysis supports APOBEC as a major source of mutations in head and neck squamous cell carcinoma","volume":"74","author":"Faden","year":"2017","journal-title":"Oral Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Faden, D.L., Kuhs, K.A.L., Lin, M., Langenbucher, A., Pinheiro, M., Yeager, M., Cullen, M., Boland, J.F., Steinberg, M., and Bass, S. (2021). APOBEC Mutagenesis Is Concordant between Tumor and Viral Genomes in HPV-Positive Head and Neck Squamous Cell Carcinoma. Viruses, 13.","DOI":"10.1101\/2021.02.27.433168"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e02234-14","DOI":"10.1128\/mBio.02234-14","article-title":"Human Papillomavirus E6 Triggers Upregulation of the Antiviral and Cancer Genomic DNA Deaminase APOBEC3B","volume":"5","author":"Vieira","year":"2014","journal-title":"mBio"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.coms.2014.01.001","article-title":"Epidemiologic Trends in Head and Neck Cancer and Aids in Diagnosis","volume":"26","author":"Vigneswaran","year":"2014","journal-title":"Oral Maxillofac. Surg. Clin. N. Am."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer","volume":"363","author":"Ang","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1200\/JCO.2011.36.4596","article-title":"Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States","volume":"29","author":"Chaturvedi","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"915","DOI":"10.21037\/atm-20-6264","article-title":"Molecular landscape of head and neck cancer and implications for therapy","volume":"9","author":"Farah","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1200\/JCO.2005.04.8306","article-title":"Epidermal Growth Factor Receptor Biology in Head and Neck Cancer","volume":"24","author":"Kalyankrishna","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"813","DOI":"10.21037\/atm.2020.04.07","article-title":"EGFR in head and neck squamous cell carcinoma: Exploring possibilities of novel drug combinations","volume":"8","author":"Rehmani","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2147\/BTT.S43628","article-title":"Cetuximab: Its unique place in head and neck cancer treatment","volume":"2013","author":"Vermorken","year":"2013","journal-title":"Biol. Targets Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nrd2204","article-title":"Panitumumab","volume":"5","author":"Saltz","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1634\/theoncologist.2017-0661","article-title":"Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and\/or Metastatic Head and Neck Squamous Cell Carcinomas","volume":"23","author":"William","year":"2018","journal-title":"Oncologist"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Yamaoka, T., Ohba, M., and Ohmori, T. (2017). Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18112420"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"a031427","DOI":"10.1101\/cshperspect.a031427","article-title":"The K-Ras, N-Ras, and H-Ras Isoforms: Unique Conformational Preferences and Implications for Targeting Oncogenic Mutants","volume":"8","author":"Parker","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1200\/JCO.20.02903","article-title":"Tipifarnib in Head and Neck Squamous Cell Carcinoma with HRAS Mutations","volume":"39","author":"Ho","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ejmech.2016.01.012","article-title":"PI3K\/Akt\/mTOR and Ras\/Raf\/MEK\/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives","volume":"109","author":"Asati","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Degirmenci, U., Wang, M., and Hu, J. (2020). Targeting Aberrant RAS\/RAF\/MEK\/ERK Signaling for Cancer Therapy. Cells, 9.","DOI":"10.3390\/cells9010198"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/bs.acr.2018.02.004","article-title":"Extracellular-Regulated Kinases: Signaling from Ras to ERK Substrates to Control Biological Outcomes","volume":"Volume 138","author":"Eblen","year":"2018","journal-title":"Advances in Cancer Research"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4103\/1319-3767.37808","article-title":"Sorafenib in the treatment of advanced hepatocellular carcinoma","volume":"14","author":"Mousa","year":"2008","journal-title":"Saudi J. Gastroenterol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2006.10.2871","article-title":"Phase II Trial of Sorafenib in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma","volume":"25","author":"Elser","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1200\/JCO.2009.25.6834","article-title":"Phase II Evaluation of Sorafenib in Advanced and Metastatic Squamous Cell Carcinoma of the Head and Neck: Southwest Oncology Group Study S0420","volume":"28","author":"Williamson","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/iub.2446","article-title":"The PI3K\/Akt\/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies","volume":"73","author":"Dilmaghani","year":"2021","journal-title":"IUBMB Life"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1016\/j.bmcl.2013.05.007","article-title":"Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation","volume":"23","author":"Furet","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/1078-0432.CCR-20-3652","article-title":"FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer","volume":"27","author":"Narayan","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"7582","DOI":"10.4049\/jimmunol.180.11.7582","article-title":"Differential Involvement of I\u03baB Kinases \u03b1 and \u03b2 in Cytokine- and Insulin-Induced Mammalian Target of Rapamycin Activation Determined by Akt","volume":"180","author":"Dan","year":"2008","journal-title":"J. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/lio2.370","article-title":"mTOR inhibitor use in head and neck squamous cell carcinoma: A meta-analysis on survival, tumor response, and toxicity","volume":"5","author":"Patel","year":"2020","journal-title":"Laryngoscope Investig. Otolaryngol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.oraloncology.2006.01.005","article-title":"Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC)","volume":"43","author":"Freier","year":"2007","journal-title":"Oral Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1158\/1078-0432.CCR-15-1874","article-title":"FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma","volume":"22","author":"Koole","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.3892\/or.2017.5801","article-title":"Targeting VEGFR and FGFR in head and neck squamous cell carcinoma in vitro","volume":"38","author":"Brands","year":"2017","journal-title":"Oncol. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.oraloncology.2013.10.003","article-title":"Combination antiangiogenic therapy and radiation in head and neck cancers","volume":"50","author":"Hsu","year":"2014","journal-title":"Oral Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/annonc\/mds245","article-title":"Cetuximab and bevacizumab: Preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck","volume":"24","author":"Argiris","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(09)70002-6","article-title":"Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: A phase I\/II study","volume":"10","author":"Cohen","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"7879","DOI":"10.3892\/mmr.2017.7641","article-title":"PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics","volume":"16","author":"Ying","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Lin, L.-H., Lin, J.-S., Yang, C.-C., Cheng, H.-W., Chang, K.-W., and Liu, C.-J. (2020). Overexpression of Platelet-Derived Growth Factor and Its Receptor Are Correlated with Oral Tumorigenesis and Poor Prognosis in Oral Squamous Cell Carcinoma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21072360"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3892\/ijo.2011.912","article-title":"Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGF-R\u03b1\/\u00df expression in squamous cell carcinoma of the head and neck in vitro","volume":"38","author":"Schultz","year":"2011","journal-title":"Int. J. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12943-022-01503-1","article-title":"Molecular mechanism(s) of regulation(s) of c-MET\/HGF signaling in head and neck cancer","volume":"21","author":"Raj","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"633","DOI":"10.7150\/jca.12663","article-title":"Understanding and Targeting MET Signaling in Solid Tumors\u2014Are We There Yet?","volume":"7","author":"Ariyawutyakorn","year":"2016","journal-title":"J. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"105074","DOI":"10.1016\/j.oraloncology.2020.105074","article-title":"Combinatorial approaches targeting the EGFR family and c-Met in SCCHN","volume":"112","author":"Wang","year":"2020","journal-title":"Oral Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: From bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/hed.21468","article-title":"Prognostic significance of nuclear pSTAT3 in oral cancer","volume":"33","author":"Macha","year":"2011","journal-title":"Head Neck"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/1476-4598-12-133","article-title":"Combining radiotherapy with MEK1\/2, STAT5 or STAT6 inhibition reduces survival of head and neck cancer lines","volume":"12","author":"Stegeman","year":"2013","journal-title":"Mol. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1200\/JCO.2007.15.1613","article-title":"Cancer Stem Cells in Head and Neck Squamous Cell Cancer","volume":"26","author":"Prince","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_63","first-page":"3843","article-title":"Cancer stem cell biomarkers for head and neck squamous cell carcinoma: A bioinformatic analysis","volume":"40","author":"Xiao","year":"2018","journal-title":"Oncol. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Gunduz, M., Gunduz, E., Tamagawa, S., Enomoto, K., and Hotomi, M. (2021). Cancer Stem Cells in Oropharyngeal Cancer. Cancers, 13.","DOI":"10.3390\/cancers13153878"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1182\/blood-2005-08-3329","article-title":"Recent insights into the role of Notch signaling in tumorigenesis","volume":"107","author":"Leong","year":"2006","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1126\/science.1206923","article-title":"Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1","volume":"333","author":"Agrawal","year":"2011","journal-title":"Science"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"6308","DOI":"10.1158\/1078-0432.CCR-17-3535","article-title":"Loss of Function of Canonical Notch Signaling Drives Head and Neck Carcinogenesis","volume":"24","author":"Nyman","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1158\/0008-5472.CAN-13-1259","article-title":"Activation of the NOTCH Pathway in Head and Neck Cancer","volume":"74","author":"Sun","year":"2014","journal-title":"Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/labinvest.2015.163","article-title":"Notch1 signaling contributes to stemness in head and neck squamous cell carcinoma","volume":"96","author":"Lee","year":"2016","journal-title":"Lab. Investig."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/onc.2016.304","article-title":"Wnt signaling in cancer","volume":"36","author":"Zhan","year":"2016","journal-title":"Oncogene"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41392-021-00762-6","article-title":"Wnt\/\u03b2-catenin signalling: Function, biological mechanisms, and therapeutic opportunities","volume":"7","author":"Liu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Paluszczak, J. (2020). The Significance of the Dysregulation of Canonical Wnt Signaling in Head and Neck Squamous Cell Carcinomas. Cells, 9.","DOI":"10.3390\/cells9030723"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s13402-019-00440-4","article-title":"Inhibition of CBP\/\u03b2-catenin and porcupine attenuates Wnt signaling and induces apoptosis in head and neck carcinoma cells","volume":"42","author":"Kleszcz","year":"2019","journal-title":"Cell. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1006\/dbio.1995.0010","article-title":"Hedgehog and Bmp Genes Are Coexpressed at Many Diverse Sites of Cell\u2013Cell Interaction in the Mouse Embryo","volume":"172","author":"Bitgood","year":"1995","journal-title":"Dev. Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/383407a0","article-title":"Cyclopia and defective axial patterning in mice lacking Sonic hedgehog gene function","volume":"383","author":"Chiang","year":"1996","journal-title":"Nature"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1158\/1078-0432.CCR-12-0568","article-title":"Vismodegib","volume":"18","author":"Rudin","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4149\/neo_2021_201204N1304","article-title":"Sonic Hedgehog is a novel prognostic biomarker in patients with oral squamous cell carcinoma","volume":"68","author":"Cierpikowski","year":"2021","journal-title":"Neoplasma"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1758835920911229","DOI":"10.1177\/1758835920911229","article-title":"Widespread expression of Sonic hedgehog (Shh) and Nrf2 in patients treated with cisplatin predicts outcome in resected tumors and are potential therapeutic targets for HPV-negative head and neck cancer","volume":"12","author":"Noman","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Enzenhofer, E., Parzefall, T., Haymerle, G., Schneider, S., Kadletz, L., Heiduschka, G., Pammer, J., Oberndorfer, F., Wrba, F., and Loader, B. (2016). Impact of Sonic Hedgehog Pathway Expression on Outcome in HPV Negative Head and Neck Carcinoma Patients after Surgery and Adjuvant Radiotherapy. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0167665"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/jop.13050","article-title":"Hedgehog signaling promotes multidrug resistance by regulation of ABC transporters in oral squamous cell carcinoma","volume":"49","author":"Lu","year":"2020","journal-title":"J. Oral Pathol. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5405","DOI":"10.21873\/anticanres.15352","article-title":"SHH Expression Is Significantly Associated with Cancer Stem Cell Markers in Oral Squamous Cell Carcinoma","volume":"41","author":"Cierpikowski","year":"2021","journal-title":"Anticancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s13402-021-00591-3","article-title":"Comprehending the crosstalk between Notch, Wnt and Hedgehog signaling pathways in oral squamous cell carcinoma\u2014Clinical implications","volume":"44","author":"Patni","year":"2021","journal-title":"Cell. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ceb.2017.12.012","article-title":"The Hippo pathway in organ development, homeostasis, and regeneration","volume":"49","author":"Fu","year":"2017","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/cas.12227","article-title":"Capturing the mammalian Hippo: Elucidating its role in cancer","volume":"104","author":"Nishio","year":"2013","journal-title":"Cancer Sci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1111\/cas.14639","article-title":"Cancer stem cells and their niche in the progression of squamous cell carcinoma","volume":"111","author":"Oshimori","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_86","first-page":"4799","article-title":"Transforming growth factor-\u03b2 signaling in head and neck squamous cell carcinoma: Insights into cellular responses (Review)","volume":"16","author":"Pang","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"110329","DOI":"10.1016\/j.intimp.2023.110329","article-title":"The current advances and future directions of PD-1\/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy","volume":"120","author":"Chen","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"ref_88","first-page":"727","article-title":"PD-1\/PD-L1 pathway: Current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1080\/17425255.2016.1216976","article-title":"Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma","volume":"12","author":"Longoria","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1634\/theoncologist.2016-0496","article-title":"FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy","volume":"22","author":"Larkins","year":"2017","journal-title":"Oncologist"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the Origin of Cancer Cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Pascale, R.M., Calvisi, D.F., Simile, M.M., Feo, C.F., and Feo, F. (2020). The Warburg Effect 97 Years after Its Discovery. Cancers, 12.","DOI":"10.3390\/cancers12102819"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10555-017-9691-z","article-title":"Targeting metabolic pathways for head and neck cancers therapeutics","volume":"36","author":"Yamamoto","year":"2017","journal-title":"Cancer Metastasis Rev."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Hsieh, Y.-T., Chen, Y.-F., Lin, S.-C., Chang, K.-W., and Li, W.-C. (2019). Targeting Cellular Metabolism Modulates Head and Neck Oncogenesis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20163960"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41573-021-00339-6","article-title":"Targeting cancer metabolism in the era of precision oncology","volume":"21","author":"Stine","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1158\/1078-0432.CCR-17-1339","article-title":"Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer","volume":"24","author":"Xu","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"111386","DOI":"10.1016\/j.yexcr.2019.04.007","article-title":"Targeting the unfolded protein response in head and neck and oral cavity cancers","volume":"382","author":"Cole","year":"2019","journal-title":"Exp. Cell Res."},{"key":"ref_99","first-page":"213","article-title":"Epigenetic Modifications in Head and Neck Cancer","volume":"58","author":"Strzelczyk","year":"2019","journal-title":"Biochem. Genet."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Kordbacheh, F., and Farah, C.S. (2021). Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma. Cancers, 13.","DOI":"10.3390\/cancers13215471"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Van Harten, A.M., and Brakenhoff, R.H. (2021). Targeted Treatment of Head and Neck (Pre)Cancer: Preclinical Target Identification and Development of Novel Therapeutic Applications. Cancers, 13.","DOI":"10.3390\/cancers13112774"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Romanowska, K., Sobecka, A., Raw\u0142uszko-Wieczorek, A.A., Suchorska, W.M., and Golusi\u0144ski, W. (2020). Head and Neck Squamous Cell Carcinoma: Epigenetic Landscape. Diagnostics, 11.","DOI":"10.3390\/diagnostics11010034"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Ghosh, S., Shah, P.A., and Johnson, F.M. (2022). Novel Systemic Treatment Modalities Including Immunotherapy and Molecular Targeted Therapy for Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23147889"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Zaryouh, H., Van Loenhout, J., Peeters, M., Vermorken, J.B., Lardon, F., and Wouters, A. (2022). Co-Targeting the EGFR and PI3K\/Akt Pathway to Overcome Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma: What about Autophagy?. Cancers, 14.","DOI":"10.3390\/cancers14246128"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"678966","DOI":"10.3389\/fonc.2021.678966","article-title":"EGFR and PI3K Pathway Activities Might Guide Drug Repurposing in HPV-Negative Head and Neck Cancers","volume":"11","author":"Mock","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/hed.24560","article-title":"Combination of phosphotidylinositol-3-kinase targeting with cetuximab and irradiation: A preclinical study on an orthotopic xenograft model of head and neck cancer","volume":"39","author":"Bozec","year":"2016","journal-title":"Head Neck"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1124\/mol.118.115162","article-title":"Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma","volume":"95","author":"Michmerhuizen","year":"2019","journal-title":"Mol. Pharmacol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"697967","DOI":"10.3389\/fonc.2021.697967","article-title":"The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy","volume":"11","author":"Zaryouh","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"E156","DOI":"10.1002\/lary.25754","article-title":"Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer","volume":"126","author":"Bozec","year":"2015","journal-title":"Laryngoscope"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1158\/1535-7163.MCT-17-0115","article-title":"Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC","volume":"16","author":"Swick","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_111","first-page":"1282","article-title":"Inhibition of cisplatin-resistant head and neck squamous cell carcinoma by combination of Afatinib with PD0325901, a MEK inhibitor","volume":"9","author":"Lin","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"10696","DOI":"10.18632\/oncotarget.7372","article-title":"A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers","volume":"7","author":"Yamaguchi","year":"2016","journal-title":"Oncotarget"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"44","DOI":"10.15761\/OHNS.1000111","article-title":"Differential compensation mechanisms define resistance to PI3K inhibitors in PIK3CA amplified HNSCC","volume":"1","author":"Michmerhuizen","year":"2016","journal-title":"Otorhinolaryngol. Neck Surg."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/hed.27018","article-title":"Small molecule profiling to define synergistic EGFR inhibitor combinations in head and neck squamous cell carcinoma","volume":"44","author":"Michmerhuizen","year":"2022","journal-title":"Head Neck"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1093\/annonc\/mdp070","article-title":"Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model","volume":"20","author":"Bozec","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1158\/1078-0432.CCR-10-3339","article-title":"Dual Blockade of EGFR and c-Met Abrogates Redundant Signaling and Proliferation in Head and Neck Carcinoma Cells","volume":"17","author":"Xu","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Bonner, J.A., Trummell, H.Q., Bonner, A.B., Willey, C.D., Bredel, M., and Yang, E.S. (2015). Enhancement of Cetuximab-Induced Radiosensitization by JAK-1 Inhibition. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1679-x"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e12424","DOI":"10.1111\/cpr.12424","article-title":"Combined Erlotinib and PF-03084014 treatment contributes to synthetic lethality in head and neck squamous cell carcinoma","volume":"51","author":"Zheng","year":"2017","journal-title":"Cell Prolif."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Kleszcz, R., Fr\u0105ckowiak, M., Dorna, D., and Paluszczak, J. (2023). Combinations of PRI-724 Wnt\/\u03b2-Catenin Pathway Inhibitor with Vismodegib, Erlotinib, or HS-173 Synergistically Inhibit Head and Neck Squamous Cancer Cells. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241310448"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00280-017-3239-3","article-title":"Reduced proliferation and colony formation of head and neck squamous cell carcinoma (HNSCC) after dual targeting of EGFR and hedgehog pathways","volume":"79","author":"Liebig","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1158\/1535-7163.MCT-12-0101-T","article-title":"Inhibition of TGF-\u03b2 Enhances the In Vivo Antitumor Efficacy of EGF Receptor\u2013Targeted Therapy","volume":"11","author":"Bedi","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/s42003-021-02744-4","article-title":"EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1","volume":"4","author":"Ando","year":"2021","journal-title":"Commun. Biol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41416-018-0351-z","article-title":"Co-targeting EGFR and IKK\u03b2\/NF-\u03baB signalling pathways in head and neck squamous cell carcinoma: A potential novel therapy for head and neck squamous cell cancer","volume":"120","author":"Li","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s12032-021-01557-z","article-title":"Combinatorial treatment with Gefitinib and Bay11-7085 sensitizes primary Gefitinib-resistant OSCC cells by influencing the EGFR- NF\u03baB signaling axis","volume":"38","author":"Sinto","year":"2021","journal-title":"Med. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): A randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.annonc.2022.10.006","article-title":"Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): A multicenter, randomized, phase II trial","volume":"34","author":"Tao","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"105871","DOI":"10.1016\/j.oraloncology.2022.105871","article-title":"Pembrolizumab with or without chemotherapy versus cetuximab plus chemotherapy to treat recurrent or metastatic head and neck squamous cell carcinoma: An updated KEYNOTE-048 based cost-effectiveness analysis","volume":"129","author":"She","year":"2022","journal-title":"Oral Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(21)00136-4","article-title":"Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: An open-label, multi-arm, non-randomised, multicentre, phase 2 trial","volume":"22","author":"Sacco","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_129","first-page":"55","article-title":"2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells","volume":"24","author":"Sobhakumari","year":"2016","journal-title":"Oncol. Res. Featur. Preclin. Clin. Cancer Ther."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Schoenwaelder, N., Salewski, I., Engel, N., Krause, M., Schneider, B., M\u00fcller, M., Riess, C., Lemcke, H., Skorska, A., and Grosse-Thie, C. (2021). The Individual Effects of Cyclin-Dependent Kinase Inhibitors on Head and Neck Cancer Cells\u2014A Systematic Analysis. Cancers, 13.","DOI":"10.3390\/cancers13102396"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1667\/RR15480.1","article-title":"Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models","volume":"194","author":"Frederick","year":"2020","journal-title":"Radiat. Res."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Chien, M.-H., Yang, W.-E., Yang, Y.-C., Ku, C.-C., Lee, W.-J., Tsai, M.-Y., Lin, C.-W., and Yang, S.-F. (2020). Dual Targeting of the p38 MAPK-HO-1 Axis and cIAP1\/XIAP by Demethoxycurcumin Triggers Caspase-Mediated Apoptotic Cell Death in Oral Squamous Cell Carcinoma Cells. Cancers, 12.","DOI":"10.3390\/cancers12030703"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"599","DOI":"10.18632\/oncotarget.311","article-title":"Aurora Kinase Inhibition Overcomes Cetuximab Resistance in Squamous Cell Cancer of the Head and Neck","volume":"2","author":"Hoellein","year":"2011","journal-title":"Oncotarget"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"105961","DOI":"10.1016\/j.ejps.2021.105961","article-title":"The inhibitors of KDM4 and KDM6 histone lysine demethylases enhance the anti-growth effects of erlotinib and HS-173 in head and neck cancer cells","volume":"166","author":"Kleszcz","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.7150\/thno.64347","article-title":"Overcoming resistance to EGFR monotherapy in HNSCC by identification and inhibition of individualized cancer processes","volume":"12","author":"Jubran","year":"2022","journal-title":"Theranostics"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1158\/1535-7163.MCT-21-0142","article-title":"Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma","volume":"21","author":"Javaid","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"640490","DOI":"10.3389\/fonc.2021.640490","article-title":"Targeted Therapy with PI3K and FGFR Inhibitors on Human Papillomavirus Positive and Negative Tonsillar and Base of Tongue Cancer Lines with and Without Corresponding Mutations","volume":"11","author":"Holzhauser","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1158\/1078-0432.CCR-18-3276","article-title":"PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K\/mTOR Inhibition","volume":"25","author":"Sambandam","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.ejca.2015.06.115","article-title":"Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours","volume":"51","author":"Munster","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/jop.13233","article-title":"The combinatorial inhibition of Wnt signaling and Akt kinase is beneficial for reducing the survival and glycolytic activity of tongue cancer cells","volume":"51","author":"Kleszcz","year":"2021","journal-title":"J. Oral Pathol. Med."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Kleszcz, R., and Paluszczak, J. (2022). The Wnt Signaling Pathway Inhibitors Improve the Therapeutic Activity of Glycolysis Modulators against Tongue Cancer Cells. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031248"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"14803","DOI":"10.18632\/oncotarget.7543","article-title":"The CDK4\/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma","volume":"7","author":"Ku","year":"2016","journal-title":"Oncotarget"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Kostopoulou, O.N., Zupancic, M., Pont, M., Papin, E., Lukoseviciute, M., Mikelarena, B.A., Holzhauser, S., and Dalianis, T. (2022). Targeted Therapy of HPV Positive and Negative Tonsillar Squamous Cell Carcinoma Cell Lines Reveals Synergy between CDK4\/6, PI3K and Sometimes FGFR Inhibitors, but Rarely between PARP and WEE1 Inhibitors. Viruses, 14.","DOI":"10.3390\/v14071372"},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Byskata, K., Lukoseviciute, M., Tuti, F., Zupancic, M., Kostopoulou, O.N., Holzhauser, S., and Dalianis, T. (2022). Targeted Therapy with PI3K, PARP, and WEE1 Inhibitors and Radiotherapy in HPV Positive and Negative Tonsillar Squamous Cell Carcinoma Cell Lines Reveals Synergy while Effects with APR-246 Are Limited. Cancers, 15.","DOI":"10.3390\/cancers15010093"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.oraloncology.2018.07.010","article-title":"ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition","volume":"84","author":"Ruicci","year":"2018","journal-title":"Oral Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1093\/annonc\/mdv194","article-title":"Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"26","author":"Massarelli","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.oraloncology.2018.05.014","article-title":"Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent\/metastatic head and neck squamous cell carcinoma","volume":"82","author":"Ferrarotto","year":"2018","journal-title":"Oral Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","article-title":"Rational combinations of targeted cancer therapies: Background, advances and challenges","volume":"22","author":"Jin","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1610694","DOI":"10.3389\/pore.2022.1610694","article-title":"On-Target Side Effects of Targeted Therapeutics of Cancer","volume":"28","author":"Uhlyarik","year":"2022","journal-title":"Pathol. Oncol. Res."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1177\/0192623312464311","article-title":"On-target and Off-target-based Toxicologic Effects","volume":"41","author":"Rudmann","year":"2012","journal-title":"Toxicol. Pathol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2020.0812","article-title":"New Insight on Preventing EGFR Inhibitor\u2013Induced Adverse Effects","volume":"323","author":"Hampton","year":"2020","journal-title":"JAMA"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ejca.2006.11.016","article-title":"Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors","volume":"43","author":"Vos","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/17425255.2019.1663169","article-title":"Molecular basis for class side effects associated with PI3K\/AKT\/mTOR pathway inhibitors","volume":"15","author":"Zhang","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_154","first-page":"683","article-title":"The cost of molecular-guided therapy in oncology: A prospective cost study alongside the MOSCATO trial","volume":"19","author":"Foulon","year":"2017","journal-title":"Anesthesia Analg."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jgo.2020.11.007","article-title":"Rapid rise in the cost of targeted cancer therapies for Medicare patients with solid tumors from 2006 to 2015","volume":"12","author":"Wilson","year":"2020","journal-title":"J. Geriatr. Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Seo, M.K., and Cairns, J. (2018). Do cancer biomarkers make targeted therapies cost-effective? A systematic review in metastatic colorectal cancer. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0204496"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/17460441.2021.1969359","article-title":"Strategies for targeting undruggable targets","volume":"17","author":"Zhang","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"100939","DOI":"10.1016\/j.conctc.2022.100939","article-title":"Barriers for cancer clinical trial enrollment: A qualitative study of the perspectives of healthcare providers","volume":"28","author":"Kumar","year":"2022","journal-title":"Contemp. Clin. Trials Commun."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1177\/0022034518769645","article-title":"Precision Therapy of Head and Neck Squamous Cell Carcinoma","volume":"97","author":"Polverini","year":"2018","journal-title":"J. Dent. Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.drup.2018.09.001","article-title":"Precision medicine in head and neck cancer","volume":"40","author":"Gil","year":"2018","journal-title":"Drug Resist. Updat."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.2147\/IJN.S377816","article-title":"Personalized Targeted Therapeutic Strategies against Oral Squamous Cell Carcinoma. An Evidence-Based Review of Literature","volume":"2022","author":"Cao","year":"2022","journal-title":"Int. J. Nanomed."},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Koll, L., G\u00fcl, D., Elnouaem, M.I., Raslan, H., Ramadan, O.R., Knauer, S.K., Strieth, S., Hagemann, J., Stauber, R.H., and Khamis, A. (2023). Exploiting Vitamin D Receptor and Its Ligands to Target Squamous Cell Carcinomas of the Head and Neck. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054675"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.3389\/fonc.2019.01408","article-title":"Anakoinosis: Correcting Aberrant Homeostasis of Cancer Tissue\u2014Going Beyond Apoptosis Induction","volume":"9","author":"Heudobler","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Heudobler, D., Rechenmacher, M., L\u00fcke, F., Vogelhuber, M., Pukrop, T., Herr, W., Ghibelli, L., Gerner, C., and Reichle, A. (2018). Peroxisome Proliferator-Activated Receptors (PPAR)\u03b3 Agonists as Master Modulators of Tumor Tissue. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19113540"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3389\/fphar.2018.00689","article-title":"Metronomics: Intrinsic Anakoinosis Modulator?","volume":"9","author":"Nicolas","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"900985","DOI":"10.3389\/fonc.2022.900985","article-title":"Drug Repurposing by Tumor Tissue Editing","volume":"12","author":"Harrer","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.3389\/fphar.2018.01307","article-title":"Lowering Etoposide Doses Shifts Cell Demise from Caspase-Dependent to Differentiation and Caspase-3-Independent Apoptosis via DNA Damage Response, Inducing AML Culture Extinction","volume":"9","author":"Bruni","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"60704","DOI":"10.18632\/oncotarget.19610","article-title":"Peroxisome proliferator-activated receptors (PPARs) are potential drug targets for cancer therapy","volume":"8","author":"Gou","year":"2017","journal-title":"Oncotarget"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s12032-017-1040-0","article-title":"Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: A phase II trial","volume":"34","author":"Walter","year":"2017","journal-title":"Med. Oncol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"599598","DOI":"10.3389\/fphar.2021.599598","article-title":"A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung)","volume":"12","author":"Heudobler","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Majchrzak-Celi\u0144ska, A., Misiorek, J.O., Kruhlenia, N., Przybyl, L., Kleszcz, R., Rolle, K., and Krajka-Ku\u017aniak, V. (2021). COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt\/\u03b2-catenin pathway and COX-2\/PGE2\/EP4 signaling in glioblastoma cells. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08164-1"},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Papierska, K., Krajka-Ku\u017aniak, V., Paluszczak, J., Kleszcz, R., Skalski, M., Studzi\u0144ska-Sroka, E., and Baer-Dubowska, W. (2021). Lichen-Derived Depsides and Depsidones Modulate the Nrf2, NF-\u03baB and STAT3 Signaling Pathways in Colorectal Cancer Cells. Molecules, 26.","DOI":"10.3390\/molecules26164787"},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Naro\u017cna, M., Krajka-Ku\u017aniak, V., Kleszcz, R., and Baer-Dubowska, W. (2022). Indomethacin and Diclofenac Hybrids with Oleanolic Acid Oximes Modulate Key Signaling Pathways in Pancreatic Cancer Cells. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031230"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"103326","DOI":"10.1016\/j.bioorg.2019.103326","article-title":"Oleanolic acid oxime derivatives and their conjugates with aspirin modulate the NF-\u03baB-mediated transcription in HepG2 hepatoma cells","volume":"93","author":"Paluszczak","year":"2019","journal-title":"Bioorganic Chem."},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Naro\u017cna, M., Krajka-Ku\u017aniak, V., Bednarczyk-Cwynar, B., Kleszcz, R., Kujawski, J., and Baer-Dubowska, W. (2020). The Effect of Novel Oleanolic Acid Oximes Conjugated with Indomethacin on the Nrf2-ARE And NF-\u03baB Signaling Pathways in Normal Hepatocytes and Human Hepatocellular Cancer Cells. Pharmaceuticals, 14.","DOI":"10.3390\/ph14010032"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"108786","DOI":"10.1016\/j.cbi.2019.108786","article-title":"Morpholide derivative of the novel oleanolic oxime and succinic acid conjugate diminish the expression and activity of NF-\u03baB and STATs in human hepatocellular carcinoma cells","volume":"311","author":"Szaefer","year":"2019","journal-title":"Chem. Interactions"},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Naro\u017cna, M., Krajka-Ku\u017aniak, V., Bednarczyk-Cwynar, B., Kuci\u0144ska, M., Kleszcz, R., Kujawski, J., Piotrowska-Kempisty, H., Plewi\u0144ski, A., Murias, M., and Baer-Dubowska, W. (2021). Conjugation of Diclofenac with Novel Oleanolic Acid Derivatives Modulate Nrf2 and NF-\u03baB Activity in Hepatic Cancer Cells and Normal Hepatocytes Leading to Enhancement of Its Therapeutic and Chemopreventive Potential. Pharmaceuticals, 14.","DOI":"10.3390\/ph14070688"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3389\/fphar.2019.00145","article-title":"Re-establishing Apoptosis Competence in Bone Associated Cancers via Communicative Reprogramming Induced Through Notch Signaling Inhibition","volume":"10","author":"Colombo","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3389\/fonc.2020.00443","article-title":"Successful Treatment of Early Relapsed High-Risk AML After Allogeneic Hematopoietic Stem Cell Transplantation with Biomodulatory Therapy","volume":"10","author":"Kattner","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.3389\/fphar.2018.01279","article-title":"Cutaneous Leukemic Infiltrates Successfully Treated with Biomodulatory Therapy in a Rare Case of Therapy-Related High Risk MDS\/AML","volume":"9","author":"Heudobler","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"599552","DOI":"10.3389\/fphar.2021.599552","article-title":"Continuous Complete Remission in Two Patients with Acute Lymphoblastic Leukemia and Severe Fungal Infection Following Short-Term, Dose-Reduced Chemotherapy","volume":"12","author":"Harrer","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"599561","DOI":"10.3389\/fphar.2021.599561","article-title":"Biomodulatory Treatment Regimen, MEPED, Rescues Relapsed and Refractory Classic Hodgkin\u2019s Disease","volume":"12","author":"Harrer","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1080\/10428194.2022.2095627","article-title":"Biomodulatory therapy induces durable remissions in multi-system Langerhans cell histiocytosis","volume":"63","author":"Harrer","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3389\/fphar.2019.00287","article-title":"A Computational Model of Tumor Growth and Anakoinosis","volume":"10","author":"Pantziarka","year":"2019","journal-title":"Front. Pharmacol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/17\/4247\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:38:31Z","timestamp":1760128711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/17\/4247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,24]]},"references-count":185,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["cancers15174247"],"URL":"https:\/\/doi.org\/10.3390\/cancers15174247","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,24]]}}}